ArticleDigestive diseases and sciences2016
Refractory Autoimmune Hepatitis: Beyond Standard Therapy.
Article in Digestive diseases and sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments.World journal of gastroenterology · 2017Pooled it
- Autoimmune Hepatitis and Fibrosis.Journal of clinical medicine · 2023Review
- Liver Disease and Sickle Cell Disease: Auto-Immune Hepatitis more than a Coincidence; A Systematic Review of the Literature.Mediterranean journal of hematology and infectious diseases · 2023Review
- Calcineurin Inhibitors in the Treatment of Adult Autoimmune Hepatitis: A Systematic Review.Journal of clinical and translational hepatology · 2022Article
- Everolimus is Safe as a Second-/Third-Line Therapy in Pediatric Autoimmune Hepatitis.JPGN reports · 2022Article
- Article
- Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial.JGH open : an open access journal of gastroenterology and hepatology · 2020Article
- The Contribution of B Cells in Autoimmune Liver Diseases.Seminars in liver disease · 2019Review
- Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies.Journal of immunology research · 2019Review
- Novel Diagnostic and Therapeutic Strategies in Juvenile Autoimmune Hepatitis.Frontiers in pediatrics · 2019Review
- Risk and Surveillance of Cancers in Primary Biliary Tract Disease.Gastroenterology research and practice · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune hepatitis (AIH) can be difficult to control, particularly in some African-Americans. When standard therapy of prednisone and azathioprine is ineffective or poorly tolerated, alternative therapies are resorted to. We report two patients with AIH who were refractory to or intolerant of standard therapy. They initially responded to a combination of tacrolimus and MMF, but eventually developed acute flares of the disease that had to be managed with sirolimus, and in one case, rituximab, to achieve remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.